🌎 Amicus Therapeutics Upgraded, BioNTech Initiated, CRH Initiated and more…

Amicus Therapeutics Upgraded, BioNTech Initiated, CRH Initiated and…

May 14, 2024
by RJ Hamster

VIEW MY PORTFOLIO

May 14th, 2024

Bitcoin’s Record Break? (ad)

Bitcoin has surged past $70,000. Are you prepared for what’s next? Our free guide, “Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024,” is essential for staying ahead in the fast-evolving crypto market. It’s crafted for both beginners and seasoned investors. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.

Click here to download your free report and start leading in the crypto race.

Today’s Top Stories

On Shares Move Higher in Race to a New All-Time High

Sony Group, The Container Store rise; Alibaba, Smart Sand fall, Tuesday, 5/14/2024

Gold’s Price Surge: What It Means for You (Priority Gold)

What Wall Street Doesn’t Want You to Know About Alibaba Stock

Fed’s Powell downplays potential for a rate hike despite higher price pressures

Dutch Bros Gives Investors More Bang for the Buck than Starbucks

Czech power company CEZ reports net profit of $592 million in Q1, up by a quarter year-on-year

Claim Your Complimentary Bitcoin Reward (Crypto Swap Profits)

Home Depot: Earnings Mixed, Wait to Buy the Dip

Stock market today: Stocks edge higher on Wall Street, adding to gains for May

Crypto Miners Strike Gold in AI: Stocks to Watch

Xi’s visit to Hungary and Serbia brings new Chinese investment and deeper ties to Europe’s doorstep

Quick Links

MarketBeat All Access

The Crypto 9-5 Escape Plan (ad)

A brand-new guide from the host of one of the world’s largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today’s crypto market.

Click here to get instant access to the guide

Your Watchlist (Manage Your Watchlist and Monitor Your Portfolio)

Apple Inc. (AAPL)
Amazon.com, Inc. (AMZN)
- Director Jonathan Rubinstein sold 5,264 shares of the business’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $190.00, for a total transaction of $1,000,160.00. Following the transaction, the director now directly owns 104,400 shares in the company, valued at approximately $19,836,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
- (5/14) Ohio police fatally shoot Amazon warehouse guard who tried to kill supervisor, authorities say (marketbeat.com)
- (5/14) Amazon is Flying High, But Is It Now Overvalued? (gurufocus.com)
- (5/14) Amazon Web Services CEO Selipsky Is Stepping Down. Stock Falls. (barrons.com)
- (5/14) Amazon Web Services CEO Adam Selipsky steps down, senior exec Matt Garman named new CEO (geekwire.com)
- (5/14) What Wall Street Doesn’t Want You to Know About Alibaba Stock (marketbeat.com)
- (5/14) Amazon Web Services CEO to step down next month (invezz.com)
- (5/14) Amazon Workers Turn To Bots To Snatch Precious Time-Off Slots Before Colleagues: Report (msn.com)
- (5/14) Amazon’s Stock Claws Back From The Brink Igniting Optimism Despite Legal Frays With Fire TV Sticks (benzinga.com)
- (5/14) Amazon Web Services CEO Adam Selipsky to step down (cnbc.com)
- (5/14) Amazon’s cloud unit CEO to step down, firm says (reuters.com)
Alphabet Inc. (GOOGL)
- Director John L. Hennessy sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $168.08, for a total value of $252,120.00. Following the sale, the director now owns 4,391 shares in the company, valued at approximately $738,039.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
- (5/14) Alphabet’s Waymo Cars Are Being Probed. It’s About Self-Driving Tech. (barrons.com)
- (5/14) The Next Drug You Take May be Designed By A.I. (GOOGL) (marketbeat.com)
- (5/14) Alphabet Q1 Earnings Transcript (marketbeat.com)
- (5/14) Alphabet to spotlight AI innovations at developer conference (reuters.com)
- (5/14) Waymo’s robotaxis under investigation after crashes and traffic mishaps(techcrunch.com)
- (5/14) Wall Street Favorites: 3 Cybersecurity Stocks With Strong Buy Ratings for May 2024(investorplace.com)
- (5/14) 2 Top Tech Stocks That Could Make You a Millionaire (fool.com)
- (5/14) Simmons Bank Grows Position in Alphabet Inc. (NASDAQ:GOOGL) (marketbeat.com)
- (5/14) US opens probe into Alphabet’s Waymo over performance of self-driving vehicles(reuters.com)
Meta Platforms, Inc. (META)
Microsoft Co. (MSFT)
- Microsoft Co. (NASDAQ:MSFT) declared a quarterly dividend on Tuesday, March 12th. Shareholders of record on Thursday, May 16th will be paid a dividend of 0.75 per share by the software giant on Thursday, June 13th. This represents a $3.00 annualized dividend and a yield of 0.73%. The ex-dividend date of this dividend is Wednesday, May 15th.
- (5/14) Google I/O Event Expectations Run High Amid OpenAI, Microsoft Rivalry(finance.yahoo.com)
- (5/14) Billionaire Bill Gates Has 67% of His $42 Billion Portfolio in These 3 Stocks (fool.com)
- (5/14) Wall Street Favorites: 3 Cloud Computing Stocks With Strong Buy Ratings for May 2024(investorplace.com)
- (5/14) Alibaba & Microsoft Unlocking Profits: How Options Trading Can Capitalize On Earnings & Breakouts – Microsoft (NASDAQ:MSFT) (benzinga.com)
- (5/14) Forescout Forms Strategic Partnership with Microsoft to Secure Managed and Unmanaged Devices (businesswire.com)
- (5/14) The Next Drug You Take May be Designed By A.I. (MSFT) (marketbeat.com)
- (5/14) Microsoft Q3 Earnings Transcript (marketbeat.com)
- (5/14) Wall Street Favorites: 3 Cybersecurity Stocks With Strong Buy Ratings for May 2024(investorplace.com)
- (5/14) Microsoft Faces Heightened EU Scrutiny Over Teams Software: Report (msn.com)
- (5/14) Despite Microsoft’s $13B Funding, OpenAI Snubs Top Investor: Launches ChatGPT App For Apple Macs Ahead Of Windows (msn.com)

Analysts’ Upgrades

Atmos Energy (NYSE:ATO) was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $132.00 price target on the stock, up previously from $130.00. This represents a 12.8% upside from the current price of $116.97.
Enhabit (NYSE:EHAB) was upgraded by analysts at SVB Leerink LLC from an “underperform” rating to a “market perform” rating. They now have a $8.50 price target on the stock. This represents a 6.4% downside from the current price of $9.08.
Edison International (NYSE:EIX) was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $86.00 price target on the stock, up previously from $72.00. This represents a 15.1% upside from the current price of $74.71.
Edwards Lifesciences (NYSE:EW) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating.The current price is $85.34.
Expeditors International of Washington (NASDAQ:EXPD) was upgraded by analysts at BNP Paribas from an “underperform” rating to a “neutral” rating. They now have a $112.00 price target on the stock. This represents a 5.0% downside from the current price of $117.95.
Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating. They now have a $13.00 price target on the stock. This represents a 40.5% upside from the current price of $9.25.
Fortrea (NASDAQ:FTRE) was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They now have a $36.00 price target on the stock, down previously from $45.00. This represents a 24.8% upside from the current price of $28.85.
Newell Brands (NASDAQ:NWL) was upgraded by analysts at Barclays PLC from an “underweight” rating to an “equal weight” rating. They now have a $8.00 price target on the stock. This represents a 7.4% downside from the current price of $8.64.
Planet Fitness (NYSE:PLNT) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $78.00 price target on the stock, up previously from $68.00. This represents a 18.1% upside from the current price of $66.03.
Boston Beer (NYSE:SAM) was upgraded by analysts at Jefferies Financial Group Inc. from a “hold” rating to a “buy” rating. They now have a $360.00 price target on the stock, up previously from $335.00. This represents a 26.3% upside from the current price of $285.00.
Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating. They now have a $180.00 price target on the stock. This represents a 36.9% upside from the current price of $131.53.
Neuronetics (NASDAQ:STIM) was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.The current price is $2.53.
VTEX (NYSE:VTEX) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $9.00 price target on the stock. This represents a 27.7% upside from the current price of $7.05.
Expro Group (NYSE:XPRO) was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating. They now have a $27.00 price target on the stock, up previously from $18.00. This represents a 28.8% upside from the current price of $20.96.
View today’s most recent analysts’ upgrades at MarketBeat.com

Controversial CEO explains new way to amass wealth (ad)

There’s no shortage of controversial CEOs in America today…

From Elon Musk… to Disney’s Bob Iger… to JP Morgan’s Jamie Dimon…

But only one controversial CEO that I know of is willing to show you exactly how and why he cut his annual salary to $1…

Don’t miss Porter’s brand-new presentation on this subject

Analysts’ Downgrades

AirSculpt Technologies (NASDAQ:AIRS) was downgraded by analysts at SVB Leerink LLC from an “outperform” rating to a “market perform” rating. They now have a $5.00 price target on the stock, down previously from $8.25. This represents a 12.4% upside from the current price of $4.45.
Augmedix (NASDAQ:AUGX) was downgraded by analysts at Evercore ISI from an “outperform” rating to an “inline” rating. They now have a $1.50 price target on the stock, down previously from $5.00. This represents a 27.1% upside from the current price of $1.18.
Augmedix (NASDAQ:AUGX) was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating. They now have a $5.00 price target on the stock. This represents a 323.7% upside from the current price of $1.18.
Jackson Financial (NYSE:JXN) was downgraded by analysts at Keefe, Bruyette & Woods from an “outperform” rating to a “market perform” rating.The current price is $75.05.
Inotiv (NASDAQ:NOTV) was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. They now have a $3.75 price target on the stock, down previously from $11.50. This represents a 72.0% upside from the current price of $2.18.
Shimmick (NASDAQ:SHIM) was downgraded by analysts at Craig Hallum from a “buy” rating to a “hold” rating.The current price is $2.70.
Shimmick (NASDAQ:SHIM) was downgraded by analysts at Roth Mkm from a “buy” rating to a “neutral” rating. They now have a $3.50 price target on the stock, down previously from $9.00. This represents a 29.6% upside from the current price of $2.70.
View today’s most recent analysts’ downgrades at MarketBeat.com

I’ve got a question for you… (ad)

There’s no need to stare at boring charts all day long…

These moves ALWAYS start in the same hour of the day…

Click here because I need to hear from you

Analysts’ New Coverage

Arcellx (NASDAQ:ACLX) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $85.00 price target on the stock. This represents a 70.6% upside from the current price of $49.81.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) is now covered by analysts at Stephens. They set an “overweight” rating and a $25.00 price target on the stock. This represents a 149.8% upside from the current price of $10.01.
BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $50.00 price target on the stock. This represents a 74.0% upside from the current price of $28.73.
BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $113.00 price target on the stock. This represents a 41.6% upside from the current price of $79.78.
BioNTech (NASDAQ:BNTX) is now covered by analysts at Evercore ISI. They set an “inline” rating and a $100.00 price target on the stock. This represents a 8.5% upside from the current price of $92.16.
Blueprint Medicines (NASDAQ:BPMC) is now covered by analysts at Stephens. They set an “overweight” rating and a $140.00 price target on the stock. This represents a 31.9% upside from the current price of $106.15.
Perspective Therapeutics (NYSEAMERICAN:CATX) is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating and a $3.00 price target on the stock.
CI&T (NYSE:CINT) is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $4.20 price target on the stock. This represents a 19.3% upside from the current price of $3.52.
CRH (NYSE:CRH) is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating and a $110.00 price target on the stock. This represents a 33.8% upside from the current price of $82.19.
CEMEX (NYSE:CX) is now covered by analysts at Royal Bank of Canada. They set an “underperform” rating and a $9.00 price target on the stock. This represents a 14.4% upside from the current price of $7.87.
Delcath Systems (NASDAQ:DCTH) is now covered by analysts at Stephens. They set an “overweight” rating and a $25.00 price target on the stock. This represents a 248.2% upside from the current price of $7.18.
The Descartes Systems Group (NASDAQ:DSGX) (TSE:DSG) is now covered by analysts at Redburn Atlantic. They set a “neutral” rating and a $90.00 price target on the stock. This represents a 5.0% downside from the current price of $94.78.
Elevation Oncology (NASDAQ:ELEV) is now covered by analysts at Stephens. They set an “overweight” rating and a $8.00 price target on the stock. This represents a 125.4% upside from the current price of $3.55.
Exelixis (NASDAQ:EXEL) is now covered by analysts at Stephens. They set an “equal weight” rating and a $23.00 price target on the stock. This represents a 10.5% upside from the current price of $20.82.
Inovio Pharmaceuticals (NASDAQ:INO) is now covered by analysts at Stephens. They set an “overweight” rating and a $20.00 price target on the stock. This represents a 78.1% upside from the current price of $11.23.
Manhattan Associates (NASDAQ:MANH) is now covered by analysts at Redburn Atlantic. They set a “buy” rating and a $260.00 price target on the stock. This represents a 20.6% upside from the current price of $215.62.
Moderna (NASDAQ:MRNA) is now covered by analysts at Evercore ISI. They set an “in-line” rating and a $120.00 price target on the stock. This represents a 6.9% downside from the current price of $128.94.
Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $175.00 price target on the stock. This represents a 29.2% upside from the current price of $135.45.
Nurix Therapeutics (NASDAQ:NRIX) is now covered by analysts at Stephens. They set an “overweight” rating and a $20.00 price target on the stock. This represents a 34.0% upside from the current price of $14.93.
Orion Group (NYSE:ORN) is now covered by analysts at Craig Hallum. They set a “buy” rating and a $14.00 price target on the stock. This represents a 60.4% upside from the current price of $8.73.
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $1,150.00 price target on the stock. This represents a 17.5% upside from the current price of $978.63.
Sensei Biotherapeutics (NASDAQ:SNSE) is now covered by analysts at Stephens. They set an “overweight” rating and a $5.00 price target on the stock. This represents a 226.8% upside from the current price of $1.53.
SPS Commerce (NASDAQ:SPSC) is now covered by analysts at Redburn Atlantic. They set a “buy” rating and a $220.00 price target on the stock. This represents a 12.1% upside from the current price of $196.27.
Seagate Technology (NASDAQ:STX) is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $110.00 price target on the stock. This represents a 15.3% upside from the current price of $95.39.
Veru (NASDAQ:VERU) is now covered by analysts at B. Riley. They set a “buy” rating and a $5.00 price target on the stock. This represents a 250.9% upside from the current price of $1.43.
Vermilion Energy (NYSE:VET) (TSE:VET) is now covered by analysts at BMO Capital Markets. They set an “outperform” rating on the stock.The current price is $12.03.
Western Digital (NASDAQ:WDC) is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $90.00 price target on the stock. This represents a 24.7% upside from the current price of $72.19.
Weatherford International (NASDAQ:WFRD) is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $155.00 price target on the stock. This represents a 24.8% upside from the current price of $124.16.
View today’s most recent analysts’ new coverage at MarketBeat.com

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.

START YOUR 30-DAY FREE TRIAL

Calendars from MarketBeat

U.S. Analyst Ratings
Corporate Buybacks
Cryptocurrencies
Dividend Declarations
Earnings Announcements
Economic Reports
Gap Up/Down Stocks
Insider Trades
Initial Public Offerings (IPOs)
Most Active Stocks
Percentage Gainers/Decliners
Sector Performance
Short Interest
Unusual Options Volume
Unusual Trading Volume

Upgrade Your Subscription

Upgrade to MarketBeat All Access and receive your premium edition of MarketBeat Daily at 9:00 AM ET.

UPGRADE NOW

Manage Your Watchlist

View and add up to five holdings to your watchlist.

VIEW MY PORTFOLIO

Join Our Facebook Group

Join MarketBeat’s free stock discussion and trading idea group on Facebook.

JOIN NOW

Thank you for subscribing to MarketBeat!

We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that’s you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.

If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferencesor unsubscribe from these emails.

Today’s Bonus Content: 2024’s Must-Watch Stocks! (Click to Opt-in)

primaryinvestmentnews.com

Discharged US Marine Threatened to Target White People in Mass Shooting, Feds Say

RJ Hamster

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Amicus Therapeutics Upgraded, BioNTech Initiated, CRH Initiated and more…

Amicus Therapeutics Upgraded, BioNTech Initiated, CRH Initiated and…

Like this:

What can we do to improve this website?

Amicus Therapeutics Upgraded, BioNTech Initiated, CRH Initiated and more…

Amicus Therapeutics Upgraded, BioNTech Initiated, CRH Initiated and…

Share this:

Like this:

Related articles